Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3058% above fair value
$0.99−0.12 (-10.78%)
Close on Nov 12, 2026Market cap $250.45MP/E –Yield –
Lineage Cell Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Lineage Cell Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -280.3%. For fiscal 2025 it was -251.6%, against -226.1% the year before. The highest annual figure on record is -153.2% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -251.6% | −25.5 |
| FY2024 | Dec 31, 2024 | -226.1% | +50.4 |
| FY2023 | Dec 31, 2023 | -276.5% | −123.3 |
| FY2022 | Dec 31, 2022 | -153.2% | +980.5 |
| FY2021 | Dec 31, 2021 | -1133.6% | +314.7 |
| FY2020 | Dec 31, 2020 | -1448.4% | −342.4 |
| FY2019 | Dec 31, 2019 | -1106.0% | −268.1 |
| FY2018 | Dec 31, 2018 | -837.9% | +287.1 |
| FY2017 | Dec 31, 2017 | -1125.0% | −129.4 |
| FY2016 | Dec 31, 2016 | -995.6% | −60.2 |
| FY2015 | Dec 31, 2015 | -935.3% | +31.2 |
| FY2014 | Dec 31, 2014 | -966.5% | +296.2 |
| FY2013 | Dec 31, 2013 | -1262.7% | −624.1 |
| FY2012 | Dec 31, 2012 | -638.5% | −217.1 |
| FY2011 | Dec 31, 2011 | -421.4% | −155.7 |
| FY2010 | Dec 31, 2010 | -265.7% | −82.8 |
| FY2009 | Dec 31, 2009 | -182.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -510.0% | −407.2 |
| Q2 FY2026 | Jun 30, 2026 | -834.7% | −119.3 |
| Q1 FY2026 | Mar 31, 2026 | -440.2% | −7.1 |
| Q4 FY2025 | Dec 31, 2025 | -99.1% | +79.1 |
| Q3 FY2025 | Sep 30, 2025 | -102.9% | −1.2 |
| Q2 FY2025 | Jun 30, 2025 | -715.4% | −298.7 |
| Q1 FY2025 | Mar 31, 2025 | -433.1% | +28.2 |
| Q4 FY2024 | Dec 31, 2024 | -178.2% | +126.5 |
| Q3 FY2024 | Sep 30, 2024 | -101.6% | +436.5 |
| Q2 FY2024 | Jun 30, 2024 | -416.7% | −260.9 |
| Q1 FY2024 | Mar 31, 2024 | -461.3% | −182.9 |
| Q4 FY2023 | Dec 31, 2023 | -304.7% | +42.0 |
| Q3 FY2023 | Sep 30, 2023 | -538.1% | −363.0 |
| Q2 FY2023 | Jun 30, 2023 | -155.8% | −62.8 |
| Q1 FY2023 | Mar 31, 2023 | -278.4% | −156.2 |
| Q4 FY2022 | Dec 31, 2022 | -346.7% | +2071.0 |
| Q3 FY2022 | Sep 30, 2022 | -175.2% | +126.3 |
| Q2 FY2022 | Jun 30, 2022 | -93.0% | +1289.8 |
| Q1 FY2022 | Mar 31, 2022 | -122.1% | +1680.9 |
| Q4 FY2021 | Dec 31, 2021 | -2417.6% | −760.7 |
| Q3 FY2021 | Sep 30, 2021 | -301.5% | +876.3 |
| Q2 FY2021 | Jun 30, 2021 | -1382.8% | +275.7 |
| Q1 FY2021 | Mar 31, 2021 | -1803.1% | −356.0 |
| Q4 FY2020 | Dec 31, 2020 | -1656.9% | −1103.2 |
| Q3 FY2020 | Sep 30, 2020 | -1177.8% | +307.6 |
| Q2 FY2020 | Jun 30, 2020 | -1658.5% | −269.5 |
| Q1 FY2020 | Mar 31, 2020 | -1447.1% | −72.0 |
| Q4 FY2019 | Dec 31, 2019 | -553.7% | +779.6 |
| Q3 FY2019 | Sep 30, 2019 | -1485.4% | −430.7 |
| Q2 FY2019 | Jun 30, 2019 | -1389.1% | −1030.1 |
| Q1 FY2019 | Mar 31, 2019 | -1375.1% | +363.4 |
| Q4 FY2018 | Dec 31, 2018 | -1333.4% | −321.4 |
| Q3 FY2018 | Sep 30, 2018 | -1054.7% | −473.2 |
| Q2 FY2018 | Jun 30, 2018 | -359.0% | +1918.6 |
| Q1 FY2018 | Mar 31, 2018 | -1738.5% | +1643.5 |
| Q4 FY2017 | Dec 31, 2017 | -1012.0% | +8.3 |
| Q3 FY2017 | Sep 30, 2017 | -581.5% | – |
| Q2 FY2017 | Jun 30, 2017 | -2277.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -3382.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -1020.2% | – |
See a number that looks wrong?